filings.toolsItem 1A. RISK FACTORS
3K characters. Original on sec.gov ·
Item 1A. RISK FACTORS
There have been no material changes to the risk factors disclosed in our annual report on Form 10-K for the year ended December 31, 2022. However, to the extent SBx 1-2 discussed in Note 2 of Condensed Notes to Consolidated Financial Statements adversely affects our business, financial condition, results of operations, and liquidity, it may also have the effect of heightening many of the other risks described in such risk factors.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES, USE OF PROCEEDS, AND ISSUER PURCHASES OF EQUITY SECURITIES
Issuer Purchases of Equity Securities
The following table discloses purchases of shares of our common stock made by us or on our behalf during the third quarter of 2023.
| Period | Total Number of Shares Purchased (a) | Average Price Paid per Share (b) | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs | Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs (c) | ||||||||||||||||||||||||||||
| July 2023 | 8,180 | $ | 118.01 | — | $2.5 billion | |||||||||||||||||||||||||||
| August 2023 | 4,218,383 | $ | 131.38 | 4,214,764 | $1.9 billion | |||||||||||||||||||||||||||
| September 2023 | 8,578,599 | $ | 143.59 | 8,576,013 | $3.1 billion | |||||||||||||||||||||||||||
| Total | 12,805,162 | $ | 139.55 | 12,790,777 | $3.1 billion |
(a)The shares reported in this column include 14,385 shares related to our purchases of shares from our employees and non-employee directors in connection with the exercise of stock options, the vesting of restricted stock, and other stock compensation transactions in accordance with the terms of our stock-based compensation plans.
(b)The average price paid per share reported in this column excludes brokerage commissions and a one percent excise tax on share purchases.
(c)On February 23, 2023, we announced that our Board authorized us to purchase shares of our outstanding common stock for a total cost of up to $2.5 billion with no expiration date. As of September 30, 2023, we had $649 million remaining available for purchase under the February 2023 Program. On September 15, 2023, we announced that our Board authorized us to purchase shares of our outstanding common stock for a total cost of up to $2.5 billion with no expiration date, which is in addition to the amount remaining under the February 2023 Program.
Previous: Item 4. CONTROLS AND PROCEDURES · Next: Item 5. OTHER INFORMATION